TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immune-oncology company, and Kineta (OTC Pink:KANT), a clinical-stage biotechnology company, announced that stockholders of both companies have approved their proposed merger. At TuHURA's Special Meeting, stockholders approved increasing authorized shares to 200 million and reincorporating in Delaware. The merger is expected to close upon satisfaction of remaining closing conditions.
Both companies specialize in developing novel immunotherapies in oncology, focusing on addressing cancer immune resistance. The final voting results will be reported in Current Reports on Form 8-K with the SEC.
TuHURA Biosciences (NASDAQ:HURA), un'azienda di immuno-oncologia in fase 3, e Kineta (OTC Pink:KANT), una societ脿 biotecnologica in fase clinica, hanno annunciato che gli azionisti di entrambe le societ脿 hanno approvato la fusione proposta. Durante l'Assemblea Straordinaria di TuHURA, gli azionisti hanno approvato l'aumento delle azioni autorizzate a 200 milioni e la reincorporazione in Delaware. La fusione 猫 prevista concludersi al soddisfacimento delle condizioni residue per la chiusura.
Entrambe le societ脿 sono specializzate nello sviluppo di nuove immunoterapie oncologiche, con un focus sulla resistenza immunitaria al cancro. I risultati finali della votazione saranno comunicati nei Rapporti Correnti sul Modulo 8-K presso la SEC.
TuHURA Biosciences (NASDAQ:HURA), una compa帽铆a de inmuno-oncolog铆a en fase 3, y Kineta (OTC Pink:KANT), una empresa biotecnol贸gica en etapa cl铆nica, anunciaron que los accionistas de ambas compa帽铆as aprobaron la fusi贸n propuesta. En la Junta Especial de TuHURA, los accionistas aprobaron aumentar las acciones autorizadas a 200 millones y reincorporarse en Delaware. Se espera que la fusi贸n se cierre una vez que se cumplan las condiciones restantes.
Ambas compa帽铆as se especializan en el desarrollo de nuevas inmunoterapias en oncolog铆a, enfoc谩ndose en abordar la resistencia inmune al c谩ncer. Los resultados finales de la votaci贸n se reportar谩n en los Informes Corrientes en el Formulario 8-K ante la SEC.
TuHURA Biosciences (NASDAQ:HURA)電� 3靸� 氅挫棴頃晹鞝� 臧滊皽 須岇偓鞚措┌, Kineta (OTC Pink:KANT)電� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 鞏戩偓 欤检＜霌れ澊 鞝滌晥霅� 頃╇硲鞚� 鞀轨澑頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. TuHURA 韸闺硠 欤检＜齑濏殞鞐愳劀 欤检＜霌れ潃 鞀轨澑霅� 欤检嫕 靾橂ゼ 2鞏� 欤�搿� 電橂Μ瓿� 雿鸽澕鞗柎搿� 鞛摫搿濏晿電� 鞎堦贝鞚� 鞀轨澑頄堨姷雼堧嫟. 頃╇硲鞚� 雮潃 毵堦皭 臁瓣贝鞚� 於╈”霅橂姅 雽�搿� 鞕勲霅� 鞓堨爼鞛呺媹雼�.
鞏戩偓電� 鞎� 氅挫棴 鞝�頃劚鞚� 攴闺车頃橁赴 鞙勴暅 靸堧鞖� 氅挫棴頃晹鞝� 臧滊皽鞐� 欤茧牓頃橁碃 鞛堨姷雼堧嫟. 斓滌 韴憸 瓴瓣臣電� SEC鞐� 鞝滌稖霅橂姅 Form 8-K 順勴櫓 氤搓碃靹滌棎 瓿店皽霅� 鞓堨爼鞛呺媹雼�.
TuHURA Biosciences (NASDAQ:HURA), une soci茅t茅 d'immuno-oncologie en phase 3, et Kineta (OTC Pink:KANT), une soci茅t茅 biotechnologique en phase clinique, ont annonc茅 que les actionnaires des deux soci茅t茅s ont approuv茅 leur fusion propos茅e. Lors de l'assembl茅e sp茅ciale de TuHURA, les actionnaires ont approuv茅 l'augmentation des actions autoris茅es 脿 200 millions et la r茅incorporation dans le Delaware. La fusion devrait 锚tre finalis茅e une fois les conditions restantes remplies.
Les deux soci茅t茅s se sp茅cialisent dans le d茅veloppement de nouvelles immunoth茅rapies en oncologie, en se concentrant sur la r茅sistance immunitaire au cancer. Les r茅sultats finaux du vote seront publi茅s dans les rapports actuels sur le formulaire 8-K aupr猫s de la SEC.
TuHURA Biosciences (NASDAQ:HURA), ein Unternehmen der Phase-3-Immunonkologie, und Kineta (OTC Pink:KANT), ein biotechnologisches Unternehmen in klinischer Phase, gaben bekannt, dass die Aktion盲re beider Unternehmen der vorgeschlagenen Fusion zugestimmt haben. Bei der au脽erordentlichen Hauptversammlung von TuHURA stimmten die Aktion盲re der Erh枚hung der genehmigten Aktien auf 200 Millionen und der Neuregistrierung in Delaware zu. Die Fusion soll abgeschlossen werden, sobald die verbleibenden Abschlussbedingungen erf眉llt sind.
Beide Unternehmen sind auf die Entwicklung neuartiger Immuntherapien in der Onkologie spezialisiert und konzentrieren sich darauf, die Immunresistenz von Krebs zu 眉berwinden. Die endg眉ltigen Abstimmungsergebnisse werden in den aktuellen Berichten auf Formular 8-K bei der SEC ver枚ffentlicht.
- Merger approval received from stockholders of both companies
- Increased share authorization to 200 million shares provides more financial flexibility
- Combined expertise in immune-oncology and cancer immunotherapy development
- Strategic consolidation of two complementary biotechnology companies
- Potential share dilution due to increased share authorization
- Integration challenges and execution risks in merging two biotech companies
- Remaining closing conditions could delay merger completion
Additionally, Kineta stockholders approved the proposed merger (the "Merger") with TuHURA at Kineta's Special Meeting of Stockholders held today, June 23, 2025 (the "Kineta Special Meeting"). The parties anticipate that the Merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.
The final voting results of the TuHURA Special Meeting and the Kineta Special Meeting will be reported in Current Reports on Form 8-K filed with the
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda庐聽(pembrolizumab) compared to Keytruda庐聽plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit聽www.tuhurabio.com聽and connect with TuHURA on聽Facebook,听X, and聽LinkedIn.
About Kineta
Kineta, Inc. (OTC Pink: KANT) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients' lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. Kineta's immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit .
Through the combination of unique epitope binding and an optimized IgG1 Fc region, KVA12123 has demonstrated strong tumor growth inhibition as both a monotherapy and in combination with other checkpoint inhibitors in preclinical models. KVA12123 provides a novel approach to address immune suppression in the TME with a mechanism of action that is differentiated and complementary with T cell focused therapies. KVA12123 may be an effective immunotherapy for many types of cancer including non-small cell lung carcinoma (NSCLC), colorectal, renal cell carcinoma, head and neck, and ovarian cancer.
In February 2024, Kineta announced a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring included a significant workforce reduction and the suspension of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. At that time, Kineta also announced that it was exploring strategic alternatives to maximize stockholder value.
IMPORTANT ADDITIONAL INFORMATION REGARDING PROPOSED MERGER WITH KINETA
In connection with the Merger, TuHURA filed with the
A definitive copy of the definitive Joint Proxy Statement/Prospectus was mailed to Kineta and TuHURA stockholders beginning May 23, 2025. Investors and stockholders may obtain free copies of the documents filed or that will be filed with the SEC by TuHURA through the website maintained by the SEC at . The documents filed by TuHURA with the SEC may also be obtained free of charge at TuHURA's website at or upon written request to: TuHURA, 10500 University Drive, Suite 110,
NO OFFER OR SOLICITIATION
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Merger and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy the securities of TuHURA or Kineta, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, (i) the risk that the conditions to the closing of the Merger are not satisfied; (ii) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; (iii) uncertainties as to the timing of the consummation of the Merger and the ability of each of TuHURA and Kineta to consummate the Merger; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger; (v) unexpected costs, charges or expenses resulting from the Merger; (vi) competitive responses to the Merger; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger; (viii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (ix) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (x) risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results; and (xi) other risks and uncertainties described in detail in TuHURA's and Kineta's respective registration statements, reports and other filings with the SEC, which are available on TuHURA's and Kineta's respective websites, and at .
The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA and Kineta do not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Investor Contact:
Monique Kosse
Gilmartin Group
[email protected]
View original content to download multimedia:
SOURCE TuHURA Biosciences, Inc.
FAQ
What is the status of the merger between TuHURA Biosciences (NASDAQ:HURA) and Kineta?
What proposals did TuHURA Biosciences stockholders approve at the Special Meeting?
What are the main focus areas of TuHURA Biosciences and Kineta?
Where will the voting results of the Special Meetings be reported?
